Literature DB >> 16118456

Modeling liver fibrosis in rodents.

Christothea Constandinou1, Neil Henderson, John P Iredale.   

Abstract

Animal models of hepatic fibrosis provide a means to study the cell and molecular mediators of fibrosis in a serial manner during both progression and recovery. Several approaches to induction of fibrosis have been described. Of these, CCl(4) intoxication in rats and mice is probably the most widely studied. In addition, the CCl(4) model is the best characterized with respect to histological, biochemical, cell, and molecular changes associated with the development of fibrosis. CCl(4) can be given intraperitoneally or by oral gavage; it induces zone III necrosis and hepatocyte apoptosis with associated hepatic stellate cell activation and tissue fibrosis. With repetitive dosing CCl(4) can be used to induce bridging hepatic fibrosis (4 wk of twice-weekly dosing), cirrhosis (8 wk of twice-weekly dosing) and advanced micronodular cirrhosis (12 wk of twice-weekly dosing). In addition, for each of these models spontaneous recovery from fibrosis can be studied after cessation of dosing. Mechanistic studies using gene knockout and transgenic animals can also be established using CCl(4). Together these models have provided unparalleled insights into the mechanisms underlying hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118456     DOI: 10.1385/1-59259-940-0:237

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  82 in total

1.  Identification of RARRES1 as a core regulator in liver fibrosis.

Authors:  Andreas Teufel; Diana Becker; Susanne N Weber; Steven Dooley; Katja Breitkopf-Heinlein; Thorsten Maass; Katrin Hochrath; Markus Krupp; Jens U Marquardt; Martin Kolb; Bernhard Korn; Christof Niehrs; Tim Zimmermann; Patricio Godoy; Peter R Galle; Frank Lammert
Journal:  J Mol Med (Berl)       Date:  2012-06-06       Impact factor: 4.599

2.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

3.  FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.

Authors:  Yaxian Kong; Hong Wang; Shuling Wang; Na Tang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

Review 4.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

5.  Mouse Models of Liver Fibrosis.

Authors:  Aashreya Ravichandra; Robert F Schwabe
Journal:  Methods Mol Biol       Date:  2021

6.  Critical role of factor XIII in the initial stages of carbon tetrachloride-induced adult liver remodeling.

Authors:  Ikuko Tsujimoto; Kei Moriya; Keiko Sakai; Gerhard Dickneite; Takao Sakai
Journal:  Am J Pathol       Date:  2011-10-19       Impact factor: 4.307

7.  Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.

Authors:  Todd R Harris; Sean Kodani; Amy A Rand; Jun Yang; Denise M Imai; Sung Hee Hwang; Bruce D Hammock
Journal:  Mol Pharmacol       Date:  2018-05-29       Impact factor: 4.436

8.  Analysis of Pathological Activities of CCN Proteins in Fibrotic Diseases: Liver Fibrosis.

Authors:  Li Chen; David R Brigstock
Journal:  Methods Mol Biol       Date:  2017

9.  An ω-3-enriched diet alone does not attenuate CCl4-induced hepatic fibrosis.

Authors:  Todd R Harris; Sean Kodani; Jun Yang; Denise M Imai; Bruce D Hammock
Journal:  J Nutr Biochem       Date:  2016-09-14       Impact factor: 6.048

10.  Reproductive age-associated fibrosis in the stroma of the mammalian ovary.

Authors:  Shawn M Briley; Susmita Jasti; Jennifer M McCracken; Jessica E Hornick; Barbara Fegley; Michele T Pritchard; Francesca E Duncan
Journal:  Reproduction       Date:  2016-09       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.